Background
==========

Breast cancer has become the leading cause of cancer death among women in developing countries (for example, China), as well as the most diagnosed malignant tumor \[[@B1]\]. There are multiple strategies for breast cancer treatment, and adjuvant chemotherapy shows great benefit in reducing disease recurrence and improving prognosis for postoperative breast cancer patients \[[@B2],[@B3]\]. Adjuvant chemotherapy is given after initial treatment with surgery, and is considered standard treatment for breast cancer patients \[[@B4]-[@B6]\]. Several studies have revealed that race, as well as marital status, may impact the receipt or completion of adjuvant chemotherapy among breast cancer patients \[[@B7]-[@B9]\]. We describe and evaluate possible factors influencing receipt of postoperative adjuvant chemotherapy among married yellow-race women with breast cancer in China.

Methods
=======

Patients and data collection
----------------------------

Females diagnosed with primary breast cancer between 1 January 1 1997 and 31 December 2005 and who received surgery treatment post-diagnosis in Qilu Hospital were collected as candidates. All cases are yellow race, married females who met clinical criteria for consideration of adjuvant chemotherapy. We retrieved and identified information from medical records. To meet our objectives, social-demographic factors and clinical-pathological characteristics of candidates including patient's age at diagnosis, comorbidities, menstrual status, rural/urban status, tumor size, lymph node status, distant metastasis, tumor stage, hormone receptor status, race, marital status, and others were abstracted.

Breast cancer cases were identified by operation and histopathological examination. Clinical-pathological parameters such as estrogen receptor (ER) and progestogen receptor (PR) were evaluated by immunological histological chemistry staining. Cases were scored positive when ≥10% of the tumor cells on the slide showed positive staining irrespective of staining intensity. Operating procedures were classified into radical mastectomy, modified radical mastectomy and breast/nipple conserving surgery. Rurality was defined according to the socioeconomic survey team of the National Bureau of Statistics of China \[[@B10]\]. Comorbid illness includes cardiovascular diseases, rheumatism, tuberculosis, liver disease and other chronic diseases excluding previous or current malignant tumors that were reported by patients or their relatives. Patients without menses for more than six months were classified as postmenopausal cases. All variables were measured as of the time of treatment. Studies have shown that receipt of neoadjuvant chemotherapy may influence decisions about adjuvant chemotherapy \[[@B7],[@B11],[@B12]\]. As a result, whether a patient had received neoadjuvant chemotherapy was identified and classified.

Data collection was performed independently by two individuals. Patients' information was abstracted and coded anonymously for all participants in the study. Written, informed consent was obtained as delineated by the protocol, which was approved by the ethical committee of Shandong University.

Statistical analyses
--------------------

We conducted univariate analyses with each of these explanatory variables using Chi-square (*χ*^*2*^) tests accompanied by two-sided *P* values. A multivariate logistic regression model evaluated the association between predictors and receipt of adjuvant chemotherapy. Because the factors that affect delivery of neoadjuvant chemotherapy are probably similar to those that affect adjuvant chemotherapy, we removed parameters of neoadjuvant chemotherapy from the multivariate analyses. Logistic regression outcomes were expressed as adjusted odds ratios (OR), with 95% confidence intervals (CI). For estrogen receptor/progestogen receptor (ER/PR) status, the predictor variable showed a significant number of missing values; therefore, we re-estimated the relevant model as a sensitivity test. All the statistics were performed using the PASW Statistics 18.0 software (SPSS Inc. Chicago, Illinois, USA), and were based on two-tailed probability. *P* values of \<0.05 were considered statistically significant.

Results
=======

During the period from 1 January 1997 to 31 December 2005, a total of 1,431 married women who were diagnosed with invasive breast cancer (pTNM stage I - IV) and who received breast surgery in Qilu Hospital was included in our analyses. Overall, 936 of these 1,431 patients (65.41%) received adjuvant chemotherapy, and patients' social-demographic and clinical-pathological characteristics were described in Table [1](#T1){ref-type="table"}. We included possible predictors into our univariate analyses, as shown in Table [2](#T2){ref-type="table"}. The percentage of rural women who received chemotherapies was significantly lower when compared with urban females (61.15% versus 67.38%, *P* = 0.021). Meanwhile, our results showed that receipt of chemotherapy was significantly associated with patient's age at diagnosis (*P* = 0.030), with older females receiving less adjuvant chemotherapy. Whether a patient received neoadjuvant chemotherapy was related to the final decision of receipt of adjuvant chemotherapy or not (*P* \<0.001). Importantly, outcomes demonstrated that lymph node status of patients was highly associated with their final decision about receipt of adjuvant chemotherapy (*P* \<0.001). In these unadjusted analyses, no significant association was found between comorbid status, menopausal status, tumor size, distant metastasis or tumor stage and receipt of chemotherapy. Moderate association was observed between hormone receptor status and receipt of chemotherapy, with a *P* value of 0.082.

###### 

Demographic and clinical characteristics of breast cancer patients

  **Variable**                          **Number of cases(N=1,431)**
  ------------------------------------ ------------------------------
  Age at diagnosis (years)             
    \<50                                            780
    50 to 69                                        572
    ≥70                                              79
  Neoadjuvant chemotherapy received    
    No                                             1,075
    Yes                                             356
  Comorbidities                        
    None                                           1,024
    One or more                                     407
  Menopausal status                    
    Premenopause                                    703
    Menopause                                       728
  Residential status                   
    Rural                                           453
    Urban                                           978
  Smoking                              
    Previous or current                              13
    Never or no report                             1,418
  Reasons for visit                    
    Self-examination                               1,404
    Physical examination                             27
  Tumor size                           
    ≤2                                             1,088
    \>2                                             214
  Lymph node metastasis                
    Negative                                        823
    Positive                                        606
  Distant metastasis                   
    Negative                                       1,421
    Positive                                         10
  Tumor stage                          
    I                                               178
    II                                              927
    III                                             198
    IV                                               10
  Hormone receptor status                             
    ER- and PR-                                     203
    ER + and/or PR+                                 648
  Histological type                                   
    IDC                                            1,164
    ILC                                              49
    Others                                          218
  Procedure                                           
    Radical mastectomy                              503
    Modified radical mastectomy                     828
    Breast/nipple conserving surgery                 55
    NOS                                              45
  Treatment                                           
    Surgery                                        1,431
    Radiotherapy                                     11
    Endocrinotherapy                                264
    Chemotherapy                                    936
    NOS                                             496

ER, estrogen receptor; PR, progestogen receptor; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; NOS, not otherwise specified.

###### 

Univariate analysis of demographic and clinical factors associated with receipt of adjuvant chemotherapy

  ------------------------------------------------------------------------------------------------------------------
  **Variable**                 **Number of cases**\   **Percent that received adjuvant**\  ***χ***^***2***^***P***
                                  **(N=1,431)**             **chemotherapy(N=936)**        
  --------------------------- ---------------------- ------------------------------------- -------------------------
  Age at diagnosis (years)                                                                 

    \<50                               780                          79.62%                 0.030

    50 to 69                           572                          65.38%                  

    ≥70                                 79                          51.90%                  

  Neoadjuvant chemotherapy\                                                                
  received                                                                                 

    No                                1,075                         60.28%                 \<0.001

    Yes                                356                          80.90%                  

  Comorbidities                                                                            

    None                              1,024                         65.43%                 0.979

    One or more                        407                          65.36%                  

  Menopausal status                                                                        

    Premenopause                       703                          66.29%                 0.492

    Menopause                          728                          64.56%                  

  Residential status                                                                       

    Rural                              453                          61.15%                 0.021

    Urban                              978                          67.38%                  

  Tumor size                                                                               

    ≤2                                1,088                          67.2%                 0.369

    \>2                                214                           64.0%                  

  Lymph node metastasis                                                                    

    Negative                           823                           61.6%                 \<0.001

    Positive                           606                           70.6%                  

  Distant metastasis                                                                       

    Negative                          1,421                          65.4%                 0.759

    Positive                            10                           70.0%                  

  Tumor stage                                                                              

    I                                  178                           64.0%                 0.614

    II                                 927                           67.6%                  

    III                                198                           63.6%                  

    IV                                  10                           70.0%                  

  Hormone receptor status                                                                  

    ER- and PR-                        203                          61.58%                 0.082

    ER + and/or PR+                    648                          71.91%                  
  ------------------------------------------------------------------------------------------------------------------

ER, estrogen receptor; PR, progestogen receptor.

Then we estimated the adjusted values by controlling covariates using multivariate logistic regression model, as shown in Table [3](#T3){ref-type="table"}. Interestingly, the statistical pattern of result did not change, and the significant association demonstrated in the univariate analyses still existed in the multivariate analyses, with the exception of neoadjuvant status, a parameter that had been removed from the analytic models. Receipt of chemotherapy was significantly associated with age at diagnosis, rural--urban disparities, and lymph node status of patients. The difference between age \<50 and age ≥70 was significant (OR = 0.407, 95% CI = 0.209 to 0.792, *P* =0.008), though no significant difference was found between age \<50 and age 50 to 64 groups (*P* = 0.319). More urban females received adjuvant chemotherapy than rural ones after adjusting r other parameters (OR = 1.381, 95% CI = 1.083 to 1.761, *P* = 0.009). Patients with positive lymph node metastases received adjuvant chemotherapy more often than patients with negative cases of lymph node metastases (OR = 1.600, 95% CI = 1.266 to 2.022, *P* \<0.001). Moderate association was also observed between hormone receptor status and receipt of adjuvant chemotherapy, though it was still not statistically significant (*P* = 0.066). Because ER/PR status is an important pathological factor and because observations on this variable were missing for 38.71% of the cases, we performed a sensitivity analysis to verify our result (not shown). We re-estimated the logistic regression model (1) by excluding hormone receptor (ER/PR) status or (2) by only accepting the remaining 887 patients with ER/PR information. No change in sign or patterns of statistical significance was found for any of them.

###### 

Logistic regression analysis of demographic and clinical factors associated with receipt of adjuvant chemotherapy

  **Variable**               **OR**^**a**^   **95%CI**^**a**^   **Adjusted*P***^**a**^
  -------------------------- --------------- ------------------ ------------------------
  Age at diagnosis (years)                                      
    \<50                     Referent                            
    50 to 69                 0.769           0.463 to 1.275     0.308
    ≥70                      0.410           0.212 to 0.793     0.008
  Comorbidities                                                 
    None                     Referent                            
    One or more              1.033           0.791 to 1.349     0.811
  Menopausal status                                             
    Premenopause             Referent                            
    Menopause                1.205           0.734 to 1.979     0.461
  Residential status                                            
    Rural                    Referent                            
    Urban                    1.381           1.083 to 1.761     0.009
  Tumor size                                                    
    ≤2                       Referent                            
    \>2                      0.828           0.603 to 1.136     0.242
  Lymph node metastasis                                         
    Negative                 Referent                            
    Positive                 1.600           1.266 to 2.022     \<0.001
  Distant metastasis                                            
    Negative                 Referent                            
    Positive                 1.123           0.282 to 4.475     0.869
  Hormone receptor status                                       
    ER- and PR-              Referent                            
    ER + and/or PR+          1.364           0.979 to 1.900     0.066

^a^Adjusted using multivariate logistic regression model.

ER, estrogen receptor; PR, progestogen receptor; OR, odds ratios; CI, confidence intervals.

Previous studies have mentioned that receipt of neoadjuvant chemotherapy could influence a patient's decisions about receipt of adjuvant chemotherapy \[[@B7],[@B11],[@B12]\]. Consequently, we excluded patients who had received neoadjuvant chemotherapy (as have other studies mentioned above) and re-estimated the logistic regression model in Table [4](#T4){ref-type="table"}. Overall, 1,075 patients were included, and there were no changes in sign or patterns of statistical significance for any of the parameters. Because the factors that affect delivery of neoadjuvant chemotherapy are probably similar to those that affect adjuvant chemotherapy, and because women get all of their chemotherapy as neoadjuvant in some countries, we also re-estimate our analytic model by combining neoadjuvant and/or adjuvant chemotherapy as dependent variables, as shown in Table [5](#T5){ref-type="table"}. A moderately significant association was observed between rural--urban disparities and receipt of adjuvant chemotherapy, with a *P* value of 0.072. No changes in sign or patterns of statistical significance were observed for the remaining factors.

###### 

Logistic regression analysis of factors associated with receipt of adjuvant chemotherapy among patients not receiving neoadjuvant chemotherapy

  **Variable**                 **OR**^**a**^   **95%CI**^**a**^   **Adjusted*P***^**a**^
  ---------------------------- --------------- ------------------ ------------------------
  Age at diagnosis (years)                                        
    \<50                       Referent                            
    50 to 69                   0.690           0.386 to 1.234     0.211
    ≥70                        0.303           0.143 to 0.643     0.002
  Comorbidities                                                   
    None                       Referent                            
    One or more                1.090           0.810 to 1.467     0.568
  Menopausal status                                               
    Premenopause               Referent                            
    Menopause                  1.374           0.778 to 2.428     0.274
  Residential status                                              
    Rural                      Referent                            
    Urban                      1.398           1.058 to 1.846     0.018
  Tumor size                                                      
    ≤2                         Referent                            
    \>2                        0.799           0.510 to 1.150     0.198
  Lymph node metastasis                                           
    Negative                   Referent                            
    Positive                   1.383           1.057 to 1.809     0.018
  Distant metastasis                                              
    Negative                   Referent                            
    Positive                   1.908           0.191 to 19.015    0.582
  Hormone receptor status^a^                                      
    ER- and PR-                Referent                            
    ER + and/or PR+            1.425           0.981 to 2.070     0.063

^a^Adjusted using multivariate logistic regression model.

ER, estrogen receptor; PR, progestogen receptor; OR, odds ratios; CI, confidence intervals.

###### 

**Logistic regression analysis of demographic and clinical factors associated with receipt of adjuvant and**/**or neoadjuvant chemotherapy**

  **Variable**               **OR**^**a**^   **95%CI**^**a**^   **Adjusted*P***^**a**^
  -------------------------- --------------- ------------------ ------------------------
  Age at diagnosis (years)                                      
    \<50                     Referent                            
    50 to 69                 0.701           0.407 to 1.207     0.200
    ≥70                      0.337           0.169 to 0.674     0.002
  Comorbidities                                                 
    None                     Referent                            
    One or more              1.075           0.813 to 1.420     0.613
  Menopausal status                                             
    Premenopause             Referent                            
    Menopause                1.319           0.773 to 2.249     0.310
  Residential status                                            
    Rural                    Referent                            
    Urban                    1.265           0.979 to 1.633     0.072
  Tumor size                                                    
    ≤2                       Referent                            
    \>2                      1.266           0.888 to 1.804     0.192
  Lymph node metastasis                                         
    Negative                 Referent                            
    Positive                 1.933           1.508 to 2.477     \<0.001
  Distant metastasis                                             
    Negative                 Referent                            
    Positive                 2.639           0.326 to 21.335    0.363
  Hormone-receptor status                                       
    ER- and PR-              Referent                            
    ER + and/or PR+          1.392           0.986 to 1.964     0.060

^a^Adjusted using multivariate logistic regression model.

ER, estrogen receptor; PR, progestogen receptor; OR, odds ratios; CI, confidence intervals.

All the logistic regression models adopted in this study exhibited high goodness-of-fit, with a Hosmer-Lemeshow goodness-of-fit *P* value of 0.996 in Table [3](#T3){ref-type="table"} and above 0.500 in all logistic models.

Discussion
==========

Receipt of proper adjuvant chemotherapy for breast cancer patients is very important and associated with prognosis of breast cancer patients. Both clinical trials and consensus guidelines have identified subsets of women with breast cancer who are able to gain benefit from adjuvant chemotherapy \[[@B4],[@B13]-[@B15]\]. Many factors, including age, comorbidities, marital status, variation in provider recommendation, medical insurance, and life expectancy, are associated with whether women receive adjuvant chemotherapy and have been reported for a long time \[[@B12],[@B16]-[@B20]\]. Married women usually enjoy overall better health and higher socioeconomic status than unmarried ones, which may translate into better access to healthcare and other benefits. Meanwhile, marriage may reflect a healthy selection bias, and one study has reported that those with psychiatric or physical impairments may be less likely to marry \[[@B21]\]. Marriage may also influence the lifestyle and behaviors of women, including diet, exercise, and health screening, which may be mediating factors when making better medical choices \[[@B22]\]. On the other hand, marriage could offer better social support networks \[[@B23]\], indicating better financial support and receipt of more sensible advice, which could influence a woman's choice about receipt of adjuvant chemotherapy. Considering that most of our candidates were married, this study only focused on married women to reduce bias resulting from these confounding factors. Our research focused on married Chinese women who met clinical criteria for adjuvant chemotherapy, and analyzed the possible predictors about receipt of adjuvant chemotherapy. Though the recommendations and protocols for adjuvant chemotherapy changed over this period, an inpatient who was recommended for chemotherapy but refused doctors' advice would be recorded for the purpose of preventing medical accidents, so we were able to select candidates for this study. For now, only patients with invasive breast cancers are recommended for adjuvant chemotherapy generally, and we performed secondary selection only accepting patients diagnosed with invasive breast cancers, in line with current research. Because health care in China is a government-run project and most of our patients on record were covered by this basic medical insurance system, we did not take individual financial income of breast cancer patients into consideration.

In the univariate analyses, we found that 65.41% of the patients in this research have received postoperative adjuvant chemotherapy. Age at diagnosis, rural--urban disparities, and receipt of neoadjuvant chemotherapy or not, significantly associated with the final decision of patients about the receipt of adjuvant chemotherapy, as shown in Table [2](#T2){ref-type="table"}. After being controlled for covariates, the differences still existed and no change in sign or patterns of statistical significance was observed in all participants and cases without receipt of neoadjuvant chemotherapy only, as shown in Table [3](#T3){ref-type="table"} and Table [4](#T4){ref-type="table"}, respectively.

Age of patients is associated with receipt of adjuvant chemotherapy and has been studied for a long time \[[@B3],[@B11],[@B16],[@B24]-[@B26]\]. Our data revealed that older women adopt adjuvant chemotherapy less than young women, especially women at least 70 years old. In the clinic, older patients are less likely to tolerate chemotherapy and more likely to adopt more conservative treatment for a better quality of remaining life, consistent with clinical reports and consensus guidelines \[[@B14],[@B24],[@B27]\]. We also found that more urban women adopted adjuvant chemotherapy than rural ones, and the difference is statistically significant. Rural--urban disparities have an influence on many aspects for Chinese females, especially on education, life style, income and so forth, and urban women usually receive a better education and make more money. All of these could result in urban women knowing the benefit of adjuvant chemotherapy better, being more willing and able to pay for their health, and being able to endure the pain and chemotherapy.

As mentioned in previous studies, receipt of neoadjuvant chemotherapy may influence the decisions about adjuvant chemotherapy \[[@B7],[@B11]\]. Our results indicate that patients who received neoadjuvant chemotherapy are more likely to receive postoperative chemotherapy (80.90% versus 60.28%, *P* \<0.001). Because the factors that affect delivery of neoadjuvant chemotherapy are probably similar to those that affect adjuvant chemotherapy, we re-estimated the predictors among females without receipt of neoadjuvant chemotherapy or combined neoadjuvant and/or adjuvant chemotherapy as one dependent variable. After that we still had similar results, which verify the predictors discovered in our analyses.

Strengths and weaknesses
------------------------

First, chemotherapy regimens adopted by patients in our study consist of CMF, CTX, CEF and so forth, and we did not include chemotherapy regimens as parameters in our analyses. However, it would make our analytic models overly complicated and affect the accuracy and stability of our results since many patients accepted chemotherapy with multiple regiments. Second, a significant number of predictor values (ER and PR status) were missing in the multivariate analytic models. Nonetheless, we re-estimated the relevant model by excluding hormone-receptor (ER/PR) status or by only accepting the remaining 887 patients with ER/PR information in the analyses, and found no change in sign or patterns of statistical significance for any of them.

Conclusions
===========

Recently the importance of understanding patients who did or did not receive advised adjuvant chemotherapy was highlighted and discussed \[[@B3],[@B7],[@B8]\]. Studies have discovered that whether a patient who met clinical criteria for adjuvant chemotherapy accepted it or not, is associated with human race, marital status, socioeconomic status, and some other demographic factors. In this study, we collected information on female breast cancer patients who are yellow race and married, and explored the predictors about receipt of adjuvant chemotherapy. Our study suggests that age at diagnosis, rural--urban disparities and lymph node status of breast cancer patients are independent predictors for the receipt of adjuvant chemotherapy among married Chinese women. Further investigations are warranted, and related public health education needs to be expanded in China.
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